



Universiteit  
Leiden

The Netherlands

## **Disrupting the transcriptional machinery to combat triple-negative breast cancer**

Noord, V.E. van der

### **Citation**

Noord, V. E. van der. (2024, April 25). *Disrupting the transcriptional machinery to combat triple-negative breast cancer*. Retrieved from <https://hdl.handle.net/1887/3748390>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3748390>

**Note:** To cite this publication please use the final published version (if applicable).

**Disrupting the  
transcriptional machinery  
to combat triple-negative  
breast cancer**

**Vera Evita van der Noord**

*Cover design:* Roshni R. Nair

*Thesis lay-out:* Vera E. van der Noord

*Printing:* Ipskamp Printing, on recycled paper

© Copyright, Vera E. van der Noord, 2024

ISBN: 978-94-6473-442-3

All rights reserved. No part of this book may be reproduced in any form or by any means without permission of the author.

# **Disrupting the transcriptional machinery to combat triple-negative breast cancer**

## **Proefschrift**

ter verkrijging van de graad van doctor aan de Universiteit Leiden,  
op gezag van rector magnificus prof.dr.ir. H. Bijl,  
volgens besluit van het college voor promoties  
te verdedigen op donderdag 25 april 2024  
klokke 15:00 uur

door

Vera Evita van der Noord  
geboren te Woerden, Nederland

in 1994

**Promotor:** Prof. dr. B. van de Water

**Co-promotor:** Dr. S.E. Le Dévédec

**Promotiecommissie:**

Prof. dr. H. Irth

Prof. dr. E.C.M de Lange

Prof. dr. J. Jonkers (Nederlands Kanker Instituut)

Prof. dr. J.W.M. Martens (Erasmus Medisch Centrum)

Prof. dr. M. Tijsterman (Leiden Universiteit Medisch Centrum)

The research described in this thesis was performed at the division Drug Discovery and Safety of the Leiden Academic Centre for Drug Research (LACDR), Leiden University (Leiden, The Netherlands). The research was financially supported by the Dutch Cancer Society (KWF) and the European Research Council (ERC).

## Table of contents

<b>Chapter 1</b>	Introduction, aim and outline of this thesis	<b>7</b>
<b>Chapter 2</b>	An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer	<b>21</b>
<b>Chapter 3</b>	Targeting the heterogeneous genomic landscape in triple-negative breast cancer through inhibitors of the transcriptional machinery	<b>49</b>
<b>Chapter 4</b>	Disruption of P-TEFb activity efficiently targets triple-negative breast cancer cells and synergizes with EGFR inhibition	<b>81</b>
<b>Chapter 5</b>	Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors	<b>111</b>
<b>Chapter 6</b>	Targeting CDK9 and CDK12 to overcome transcriptional addiction in triple-negative breast cancer	<b>151</b>
<b>Chapter 7</b>	Summary, discussion and future perspectives	<b>191</b>
<b>Appendix</b>	List of abbreviations	<b>208</b>
	Dutch summary	<b>211</b>
	List of publications	<b>216</b>
	About the author	<b>218</b>